GHRP-2 raised growth hormone about 13-fold in seven healthy men

How does GHRP-2 work?

GHRP-2 is a synthetic hexapeptide that binds GHS-R1a, the same receptor ghrelin activates. Its pharmacology is fundamentally different from that of GHRH analogs such as tesamorelin and modified GRF 1-29, which act on the GHRH receptor.

The two classes converge on the same output, pulsatile GH release from the pituitary, by different routes. GHRH analogs amplify the hypothalamic signal that tells the pituitary to release GH. Ghrelin mimetics such as GHRP-2 act more directly on pituitary somatotrophs and also suppress somatostatin's braking effect.

Ghrelin receptor signaling has downstream effects beyond the pituitary, including on appetite centers and, plausibly, on corticotroph and lactotroph cells. GHRP-2 is not a clean, single-target GH switch.

Does stacking GHRP-2 with a GHRH analog create synergy?

Synergy between GHRP-2 and a GHRH analog is plausible pharmacology that none of the four human trials behind GHRP-2's evidence grade tested. The forum claim is mechanistically coherent, because the stack hits two distinct receptor systems that both converge on GH release.

Does GHRP-2 raise growth hormone in human trials?

Yes. Four small human trials show that GHRP-2 reliably raises growth hormone, the best-established fact about the peptide.

The strongest direct evidence comes from seven lean healthy men. A continuous subcutaneous infusion of GHRP-2 raised GH area-under-curve roughly 13-fold compared with saline ^[1].

In healthy older adults, 30 days of continuous subcutaneous infusion sustained more than a 1.8-fold elevation in pulsatile GH secretion ^[3]. IGF-I, IGFBP-3 and IGFBP-5 stayed elevated for the full month, with normal safety screening throughout ^[3]. The 30-day study is the longest continuous-dosing human trial and the nearest thing to evidence that the GH effect holds over weeks rather than hours.

In critically ill patients, a 5-day infusion of GHRP-2 combined with TRH reactivated blunted pulsatile GH and TSH secretion ^[2]. IGF-I and IGF-binding proteins normalized from day two onward, shifting biochemical markers toward an anabolic state ^[2].

In GH-deficient children, 8 months of graded subcutaneous dosing increased overnight GH secretion and growth velocity with no observed toxicity, but serum IGF-I and IGFBP-3 did not rise over that period ^[4]. The trial authors attributed the flat IGF-I to the peptide's short half-life and pulsatile dosing pattern, which require longer-acting formulations for a sustained IGF-I effect ^[4]. The 8-month study is the longest human trial of any duration, but it enrolled a pediatric GH-deficiency population on a therapeutic protocol, not healthy adults self-dosing.

Does GHRP-2 help with fat loss, recovery or anti-aging?

No evidence supports GHRP-2 for fat loss, recovery or anti-aging. Every human trial measured GH, IGF-I or short-term metabolic markers, not body composition or longevity outcomes. No completed phase 3 trial exists for any wellness indication ^[5].

GHRP-2's evidence grade is C, moderate. The grade reflects real, repeated human pharmacodynamic evidence and no outcome trials for the uses people care about.

Does GHRP-2 increase appetite?

Yes. In seven lean healthy men, continuous subcutaneous GHRP-2 infusion increased ad libitum caloric intake by 35.9% compared with saline ^[1]. The result confirms the orexigenic, appetite-driving effect that ghrelin-receptor agonists are known for, a pattern traced across the human trials of ghrelin agonists and appetite.

Does GHRP-2 raise cortisol or prolactin?

GHRP-2 is expected to nudge ACTH, cortisol and prolactin release, a known class effect of ghrelin-receptor agonists that is distinct from GHRH-analog peptides. Forum shorthand treats the cortisol rise as settled.

Of the four trials behind GHRP-2's evidence grade, only the critical-illness trial measured cortisol directly. Serum cortisol did not change significantly during the 5-day GHRP-2 and TRH infusion ^[2].

The critical-illness result does not settle the question. Critically ill patients have profoundly altered cortisol physiology to begin with, so the finding does not cleanly generalize to a healthy adult using GHRP-2 for recomposition.

Is GHRP-2 approved as a drug anywhere?

Japan approved GHRP-2, under the drug name pralmorelin (KP-102D), solely as a one-time diagnostic test for GH deficiency that uses a validated GH peak cutoff, not for repeated use ^[5]. Parallel therapeutic development programs, including a US GH-deficiency treatment trial, were discontinued before reaching approval ^[5].

GHRP-2's official regulatory life is a one-shot diagnostic tool, not a chronic therapeutic.

How do GHRP-2 trial doses compare with forum protocols?

GHRP-2 trials used continuous subcutaneous pump infusion, typically around 1 mcg/kg/h ^[1]⁠^[3], while forum protocols almost universally describe bolus injections of 100 to 300 mcg, two to three times daily. The pediatric trial used graded daily subcutaneous doses of 0.3 to 3 mcg/kg/day ^[4].

Continuous steady-state infusion and repeated spikes are materially different dosing patterns, and none of the four human trials tested the bolus regimen. Extrapolating safety or efficacy from a 30-day continuous pump study to a self-administered thrice-daily injection protocol is an inferential leap the trial data do not fully support, even though both approaches target the same receptor.

Is GHRP-2 better than GHRP-6 or ipamorelin?

No head-to-head human trial has compared GHRP-2 with GHRP-6 or ipamorelin, so no ranking of the three for recomposition rests on trial evidence. Forum comparisons are mechanistic inference dressed up as settled fact. Each compound's own record is covered in the GHRP-6 evidence review and the ipamorelin evidence review.

What is still unknown about GHRP-2?

Chronic, self-administered use, the pattern most forum readers ask about, is the largest gap in the GHRP-2 record:

• Months of bolus dosing. No trial has followed healthy adults through months of self-administered, bolus-dosed GHRP-2 for body composition or recovery goals, and no data cover adults self-administering for months to years. The longest continuous human data point is 30 days, in older adults under clinical supervision, using infusion rather than injection ^[3].
• Cortisol and prolactin. None of the four trials behind GHRP-2's evidence grade characterized either hormone under chronic bolus dosing. Their one cortisol measurement comes from critically ill patients on a 5-day protocol combined with TRH ^[2], which limits how far it extends.
• Safety monitoring. GHRP-2's only regulatory approval is as a single-use diagnostic test ^[5], so essentially no formal safety monitoring infrastructure stands behind the off-label, chronic-use pattern.